Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma.

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

(NASDAQ: OABI, “OmniAb”) for the development of a novel bispecific antibody drug conjugate ... changes to the proposed structure of the Business Combination that may be required or appropriate ...

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate ... changes to the proposed structure of the Business Combination that may be required or ...

Johnson & Johnson (JNJ) announced Tuesday initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed ...

1xVEGF bispecific antibodies by its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A, a bispecific structure which leverages PD-L1 as an anchor in the tumor microenvironment ...